Human immunodeficiency virus (HIV) reverse transcriptase (RT) is an important target for chemotherapeutic agents used in the treatment of AIDS. In addition to nucleoside analogues, a number of different chemical classes of compounds have been described that show potent and selective inhibition of HIV-1 replication by acting as nonnucleoside RT inhibitors (NNRTI). These compounds include, among others, nevirapine, BHAP, TIBO, HEPT, pyridinones, TSAO, oxathiin carboxanilides and quinoxalines and their derivatives (Pauwels et al., 1990; Merluzzi et al., 1990; Goldman et al., 1991; Romero et al., 1991; Balzarini et al., 1992; Baba et al., 1994; Buckheit et al., 1996; Young et al., 1995; Kleim et al., 1995) . These compounds have no antiviral activity against HIV-2 and are targeted at a non-substrate binding site of the HIV-1 RT (Cohen et al., 1991; Dueweke et al., 1992; Esnouf et al., 1995; Das et al., 1996) . Among this type of compound, nevirapine (Boehringer Ingelheim; BI-RG-587) (Carr et al., 1996) , delavirdine (Pharmacia & Upjohn; BHAP, U90152T) (Dueweke et al., 1993) , atevirdine (Pharmacia & Upjohn; BHAP, U-87201E) (Reichman et al., 1995) , loviride ( Janssen; R89439, α-APA) (Staszewski et al., 1996) and 726) (Young et al., 1995) Richman et al., 1991) . This means the clinical benefit is short-lived. The amino acid changes in the RT responsible for resistance to NNRTIs have been well-characterized for most chemical classes and reside in the hydrophobic region of the p66 subunit of RT, which is close to, but not overlapping, the catalytic site . The most common amino acid changes are at positions 100, 101, 103, 106, 108, 181, 188 and 190 of RT (Schinazi et al., 1997) .
As with other anti-HIV compounds, the role of NNRTIs in the future will be in drug combination regimens and may help delay the emergence of multidrug-resistant virus. During our random screening programme aiming to identify new anti-HIV agents, we selected two novel pyrido [1,2a] indole derivatives, BCH-1 and BCH-2, which had good activity against HIV-1 replication in vitro. These compounds inhibited purified HIV-1 RT in an in vitro assay, but had no activity against HIV-2 and have been classified as NNRTIs. We synthesized a minimal number of analogues of these compounds, which were tested against both recombinant-RT and HIV-1 replication in order to identify a structure-activity relationship. We have also investigated the activity of the most potent compound BCH-1 against a range of characterized drug resistant viruses to identify cross-resistance patterns. Finally, we grew HIV-1 continuously in the presence of increasing concentrations of BCH-1 to determine whether resistant virus could be selected for, and identified the amino acid changes responsible for conferring resistance.
Materials and Methods
Compounds BCH-1 (2-chloro-7-hydroxy-10, 10-dimethyl-7-phenyl-10H-pyrido[1,2-a]indole-6,8-dione), BCH-2 (2-chloro-7-nitro-10,10-dimethyl-7-phenyl-10H-pyrido[1,2-a]ind ole-6,8-dione) and BCH-4 (10,10-dimethyl-7-n-butyl-10H-pyrido[1,2-a]indole-6,8-dione) were purchased from Maybridge Chemical (Tintagel, UK). BCH-3 and BCH-7 were prepared from the corresponding compounds where R 2 =H (commercially available from Maybridge Chemical) by treatment with MCPBA in CH 2 Cl 2 . BCH-6 was prepared from BCH-1 by treatment with acetic anhydride, pyridine and DMAP in CH 2 Cl 2 . The nucleosides zidovudine and didanosine were purchased from Sigma and lamivudine was provided by Glaxo Wellcome (Stevenage, UK). TheNNRTIs nevirapine and MKC-442 were provided by Boehringer Ingelheim Pharmaceuticals (Ridgefield, Conn., USA) and Mitsubishi Kasei (Yokohama, Japan), respectively. The protease inhibitor saquinavir was provided by Roche Products (Welwyn Garden City, UK).
Cells and virus
The HIV-1 strains RF and HXB2, the HIV-2 strain ROD and the T cell lines MT-4, H9 and C8166 were obtained from the MRC AIDS Directed Programme Reagent Project (MRC ADP) (NIBSC, UK). T cell lines were cultured and virus stocks of laboratory adapted strains were made as previously described (Taylor et al., 1996) . Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats (National Blood Service, Colindale, London, UK) depleted of CD8-positive cells, stimulated and cultured as previously described (Brennan et al., 1994) . Clinical isolates of HIV-1 were obtained after co-culture of PBMCs from patients with AIDS (provided by J Parkin, St Bartholomew's Medical School, London, UK) with uninfected stimulated PBMCs. The wild-type and drug-resistant strains of HIV-1 HXB2 generated by site-directed mutagenesis were obtained from the MRC ADP Reagent Project. Viruses with resistance to nevirapine were generated after replication in the presence of the compound and have been previously described (Taylor et al., 1996) . Virus strains with resistance to other NNRTIs were kindly provided by J Balzarini (Rega Institute for Medical Research, Leuven, Belgium) (Balzarini et al., 1993) .
Antiviral assays
The MTT cell viability assay was used for the assessment of antiviral activity and cytotoxicity of test compounds against both wild-type and drug-resistant strains of HIV-1 as previously described (Pauwels et al., 1988) . For p24 reduction assays, C8166 T cells, or CD8-depleted PBMCs, which had been stimulated for 3 days with 10 µg/ml phytohaemagglutinin and 10 U/ml interleukin-2 (IL-2), were infected with laboratory-adapted strains or clinical isolates of HIV-1 for 2 h at room temperature. The cells were then washed and cultured in the presence or absence of different concentrations of test compound at 37°C. After 3 days for C8166 cells and 7 days for PBMCs, the cell free culture fluid was harvested and assayed for levels of p24 viral antigen using a commercially available ELISA (Coulter, UK).
In vitro RT assay
The assay for HIV-1 RT activity was performed as described previously (Hart et al., 1992) . HIV-1 RT and 32 P]dATP, 123 mg of MS2 RNA/ml and 246 nM of primer was pre-incubated at 43°C for 30 min. The enzymatic reaction was initiated by the addition of 5 µl of a solution of HIV-1 RT (200 ng) with and without compounds at various concentrations to the substrate mixture, followed by an incubation at 43°C for 25 min. Then, the reaction was stopped by the addition of 5 µl of 100 mM tetrasodium EDTA pH 8.0. A volume of 4 µl was spotted on a DEAE filter and the paper was washed following the procedure described by Hart et al. (1992) , and radioactivity was measured using a liquid scintillation counter (1450-Microbeta, Wallac Oy, Turku, Finland).
Selection of resistant HIV-1
The wild-type HIV-1 strain RF was cultured in C8166 cells in the presence of different concentrations of BCH-1. After 7 days, the cell-free culture fluid from wells containing the highest concentration of BCH-1 and showing CPE were passaged into fresh C8166 cells and again cultured in the presence of different concentrations of inhibitor. Virus was passaged this way every 7 days. After five and 10 passages, virus was screened for drug sensitivity using C8166 cells and the MTT assay, after being grown once in the absence of inhibitor.
PCR and sequencing
Once virus resistant to BCH-1 had been selected, DNA was extracted from drug-treated virus-infected C8166 cells and the RT gene amplified by PCR as previously described (Taylor et al., 1996) . Direct sequencing of the PCR product was carried out on an Applied Biosystems ABI 310 sequencer using the Big Dye terminator cycle sequencing ready reaction kit (Applied Biosystems) according to the manufacturer's instructions, using the primers described previously (Taylor et al., 1996) .
Results

Antiviral activity
Two compounds of the same class, BCH-1 and BCH-2, were identified through our random screening programme for their activity against HIV-1. Both compounds have similar structures, however, when screened using MT-4 cells infected with HIV-1 RF in an MTT cell viability assay, BCH-1 was approximately 10-fold more active than BCH-2 (Table 1) with 50% inhibitory concentration values (IC 50 ) of 0.69 µM (±0.23 µM) and 7.2 µM (±2.05 µM), respectively. Both compounds were relatively cytotoxic in this cell line with 50% cytotoxic concentration values (CC 50 ) of 22.6 µM (±2.5 µM) for BCH-1 and 29.0 µM (±3.6 µM) for BCH-2, providing selectivity indices of only 32.7 and 4.02 respectively. Compared with zidovudine, the most selective compound, BCH-1 was approximately 10-fold less active.
The anti-HIV-1 activity of BCH-1 was confirmed by measuring the reduction in levels of p24 viral antigen in the culture fluid of treated C8166 cells infected with HIV-1 HXB2 , and in human PBMCs infected with the clinical isolates CC1, CC5 or CC15 of HIV-1 (Table 2) .
Consistent with studies on the NNRTIs nevirapine and MKC-442, BCH-1 did not show any inhibitory effect when investigated for antiviral activity against HIV-2 (Table 3) , whereas zidovudine showed a similar level of antiviral activity as seen for HIV-1. This evidence strongly indicated that BCH-1 was acting as a NNRTI. In com- parison with nevirapine and MKC-442 in the same experiment, BCH-1 had equivalent activity to nevirapine but was less potent than MKC-442 against HIV-1 (Table 3) . Further evidence that BCH-1 was acting as a inhibitor of HIV-1 RT was provided when cells chronically infected with HIV-1 were treated with the compound for 2 days and then the levels of extracellular p24 determined ( Figure  1 ). In these cells, RT activity is not necessary for virus production and as with the RT inhibitor zidovudine, BCH-1 showed no inhibitory effect on the production of p24 even at very high concentrations. This was in contrast to the protease inhibitor saquinavir, which showed the expected reduction in levels of p24 viral antigen.
BCH-1 activity in vitro on HIV-1 RT
BCH-1 and BCH-2, as well as five other synthesized compounds of the same class (structures shown in Table 4) were tested for activity against purified HIV-1 RT in vitro and for anti-HIV-1 activity in MT-4 cells (Table 4 ). RT activity was tested using [α-32 P]dATP incorporation with MS2 RNA as a template in the presence of various concentrations of test compounds. At the end of the reaction, the labelled nucleic acids were spotted on a DEAE membrane and washed with 5% NaH 2 PO 4 to remove unincorporated [α-32 P]dATP. Out of the seven compounds, only BCH-1, BCH-2 and BCH-6 showed good activity against HIV-1 RT (IC 50 values of 4 µM, 6 µM and 10 µM, respectively), which correlated with the antiviral activity seen against HIV-1. It was apparent that BCH-1 and BCH-2 had similar activity against RT, but BCH-1 was 23-fold more active against HIV-1. This difference is probably due to better cellular uptake or more favourable intracellular metabolism of BCH-1. Interestingly the three compounds showing inhibitory activity; BCH-1, BCH-2 and BCH-6, all have similar chemical features †HIV-1 HXB2 mutant viruses were generated by site-generated mutagenesis and obtained through the MRC ARP. ZDV including chlorine at position R 1 and a phenyl ring at position R 3 (Table 4) .
Activity against drug-resistant mutants
BCH-1 was tested for activity against HIV-1 strains engineered by site-directed mutagenesis to have resistance to the nucleoside RT inhibitors zidovudine (amino acid changes 67N, 70R, 215F and 219Q), didanosine (amino acid change 74V) and lamivudine (amino acid change 184V). The results from these assays indicated that BCH-1 was relatively equipotent (less than fourfold change in IC 50 ) against all of these viruses with single amino acid changes in the RT gene. However, some marginal crossresistance (sixfold) was observed when BCH-1 was tested against a virus engineered to have triple-drug resistance to zidovudine, didanosine and the NNRTI nevirapine (amino acid changes 41L, 74V, 106A and 215Y ) ( Table 5) . We also investigated the activity of BCH-1 against viruses selected after growth in the presence of the NNRTIs nevirapine, TIBO and TSAO-T with single amino acid changes in positions 100, 103, 106, 138, 181 and 188, as well as a virus with two amino acid changes at positions 106 and 188 (Table 6 ). These amino acid changes are known to confer high level resistance to a range of NNRTIs (Schinazi et al., 1997) . The results indicated that BCH-1 had similar activity against viruses with the single E138K, K103N, L100I or Y181C amino acid exchanges (less than threefold change in IC 50 ), as against the wild-type virus. However, some resistance to BCH-1 (five-and 10-fold respectively), was evident when the compound was tested against viruses with single V106A or Y188C amino acid exchanges (Table  6 ). The result obtained with the V106A mutant was consistent with that obtained with the HIV-1 HXB2 triple-drug resistant virus (Table 5) , which also had an amino change at position 106. Despite the resistance to BCH-1 conferred by these single amino acid changes, it was evident that the pyrido [1,2a] indole derivative maintained better activity than nevirapine against these mutant viruses. HIV-1 with a double V106A and Y188C mutation, however, showed high level resistance to both nevirapine and BCH-1 (>250-fold and >17-fold, respectively) ( Table 6 ).
Selection of BCH-1-resistant virus
In order to isolate variants of HIV-1 that showed reduced sensitivity to BCH-1, virus was passaged in the presence of increasing concentrations of inhibitor as described in Materials and Methods. After only five passages, virus was replicating readily at a concentration of 20 µM BCH-1, but because of the cytotoxicity of this compound we were unable to passage into higher concentrations. This virus, which had been grown in the presence of BCH-1 for 5 weeks (HIV-1 RF697BCH-1Res ), was therefore cultured once in the absence of compound and screened for sensitivity to BCH-1, nevirapine and zidovudine (Table 7) . From the results it was apparent that this virus had significantly reduced sensitivity to BCH-1 (>28-fold resistant), as well as to nevirapine (>400-fold resistant), but had sensitivity similar to the wild-type strain when tested with the nucleoside analogue zidovudine. These results indicated that in common with other NNRTIs, virus with resistance to BCH-1 could be rapidly selected for in cell culture.
PCR sequencing
In order to identify the amino acid changes in the RT gene product responsible for the reduced sensitivity to BCH-1, the RT gene from proviral DNA extracted from C8166 cells infected with HIV-1 RF697BCH-1Res was amplified using PCR. The RT gene from the wild-type HIV-1 RF strain was amplified in exactly the same way, and the PCR products then directly sequenced in parallel without cloning. This identified a clear amino acid change from tyrosine to cysteine at position 181 (TAT to TGT) and partial changes of valine to aspartic acid at position 179 (GTT to GAT). A further two passages of this virus in the presence of 20 µM BCH-1 revealed complete changes at both positions. After sequencing the wild-type HIV-1 RF population it was also apparent that there was a mixture of viruses, some with a glycine (GGG) and some with an arginine (AGG) at RT position 196. This had become fixed as an arginine residue in the BCH-1-resistant virus population.
Discussion
We have identified a series of pyrido [1,2a] indole derivatives which act as novel NNRTIs of HIV-1 and have inhibitory effects on HIV-1 replication in vitro. Limited structure-activity studies suggested that for the compounds tested, chlorine in position R 1 and a phenyl ring at position R 3 were important for the inhibitory activity. The most potent compound identified, BCH-1, had a relatively narrow selectivity index and more modifications will be needed to improve the efficacy or reduce the toxicity.
As with other NNRTIs, virus with reduced sensitivity to BCH-1 was rapidly selected for in cell culture, a phenomenon that would probably be paralled in vivo, based on previous experience with other compounds of this type . Despite the fact that rapid induction of drug resistance is a feature of this class of compound, they may still be important components of drug combination regimens in the clinic. In vitro studies have demonstrated synergistic interactions when NNRTIs are used in combination with other anti-HIV compounds, (Koup et al., 1993; Brennan et al., 1994; Chong et al., 1997; Piras et al., 1997) , supporting this premise. In addition, it has been reported that several NNRTIs when combined in vitro with lamivudine, more readily suppress viral 'breakthrough' and may delay the emergence of resistant virus (Balzarini et al., 1996a) . In relation to these observations, nevirapine, delavirdine and atevirdine have shown beneficial effects in AIDS patients, with respect to the reduction of viral load and improvement in CD4 + cell counts, when used in combination with both nucleoside RT inhibitors and protease inhibitors (Reichman et al., 1995; Carr et al., 1996; Davey et al., 1996; D'Aquila et al., 1996) . Both in vitro and in vivo studies, however, have demonstrated that such concomitant combination therapy may not prevent the emergence of multidrug resistant virus (Balzarini et al., 1996b; Schmit et al., 1996; Demeter et al., 1997) .
The amino acid changes identified in the RT of HIV-1 selected after continuous growth in the presence of BCH-1 were in positions Y181C and V179D, in, or close to, the highly hydrophilic omega loop subregion of the allosteric area (segment Tyr-181 to Tyr-188) (Mager & Walther, 1996) . The Y181C amino acid change is commonly selected in cell culture after treatment with NNRTIs and has been previously described for nevirapine, delavirdine, loviride, DMP-266, MKC-442 and others (Schinazi et al., 1997) . The V179D exchange is slightly more unusual, but has been described after treatment with DMP-266, TIBO R82913 and L-697,661 and in combination with the Y181C exchange after treatment with trovirdine (Schinazi et al., 1997) . From our results it was apparent that after growth of HIV-1 in the presence of BCH-1, the Y181C amino acid change appeared before the V179D exchange, although both appeared relatively rapidly. It was also evident from the data obtained testing BCH-1 against mutant viruses generated in the presence of nevirapine, that the Y181C mutation alone only conferred a low level of resistance to the pyrido [1,2a] indole derivative. However, in combination with the V179D amino acid change, high level resistance to both BCH-1 and nevirapine was achieved. BCH-1 was also significantly less active against viruses harbouring Y188C and V106A amino acid exchanges either alone or in combination, in common with nevirapine and a number of other NNRTIs (Schinazi et al., 1997) . The compound however, did maintain good activity against viruses selected in the presence of TIBO and TSAO-T with single L100I, K103N and E138K exchanges.
In conclusion, the identification of BCH-1 as a NNRTI of HIV-1 may be an important lead for the development of a more potent and selective molecule which could be used in combination with other drugs to treat individuals infected with HIV.
